 Silence Therapeutics PLC AIM:SLN, NASDAQ:SLN, OTC:SLNCF confirmed it will delist from trading on AIM next Monday. Silence, the developer of novel short interfering ribonucleic acid siRNA therapeutics, said its ordinary shares will stop trading at market close on 29 November, although it will retain its American depository shares, which represent three ordinary shares each, on Nasdaqs global market. 